[go: up one dir, main page]

PE20091108A1 - Aminotiazoles y sus usos - Google Patents

Aminotiazoles y sus usos

Info

Publication number
PE20091108A1
PE20091108A1 PE2008002047A PE2008002047A PE20091108A1 PE 20091108 A1 PE20091108 A1 PE 20091108A1 PE 2008002047 A PE2008002047 A PE 2008002047A PE 2008002047 A PE2008002047 A PE 2008002047A PE 20091108 A1 PE20091108 A1 PE 20091108A1
Authority
PE
Peru
Prior art keywords
alkyl
co2h
compounds
aminotiazoles
refers
Prior art date
Application number
PE2008002047A
Other languages
English (en)
Inventor
Simon Bushell
Matthew J Lamarche
Jennifer Leeds
Lewis Whitehead
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40377437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091108(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20091108A1 publication Critical patent/PE20091108A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE AMINOTIAZOLES DE FORMULA (I) DONDE R1 ES -Z-CO2H O -A-Z-CO2H; R1a ES H, -Z-CO2H, -A-Z-CO2H, ENTRE OTROS, EN DONDE Z ES ALQUILENO(C1-C10), CICLOALQUILENO(C3-C8), FENILENO, ENTRE OTROS; A ES -C(O)-, -C(O)O-, -S(O)2, ENTRE OTROS; R2a ES H, OH, OR4a, ENTRE OTROS, DONDE R4a ES H O ALQUILO; R2b ES H, ALQUILO, ENTRE OTROS; R3 Y R12 SON CADA UNO H, HALOGENO, OR4b, ENTRE OTROS, DONDE R4b ES ALQUILO O -(CH2-CH2-O-)n-R9, EN DONDE R9 ES H, ALQUILO O CH2CO2H; R5 ES H, ALQUILO O R4b; n ES DE 1 A 60000. SON COMPUESTOS PREFERIDOS: (a), (b), ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL FACTOR DE ELONGACION EF-Tu BACTERIANO SIENDO UTILES EN EL TRATAMIENTO DE LAS INFECCIONES BACTERIANAS
PE2008002047A 2007-12-12 2008-12-10 Aminotiazoles y sus usos PE20091108A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1312207P 2007-12-12 2007-12-12
US2470908P 2008-01-30 2008-01-30

Publications (1)

Publication Number Publication Date
PE20091108A1 true PE20091108A1 (es) 2009-08-24

Family

ID=40377437

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002047A PE20091108A1 (es) 2007-12-12 2008-12-10 Aminotiazoles y sus usos

Country Status (26)

Country Link
US (4) US8426356B2 (es)
EP (1) EP2229386B1 (es)
JP (2) JP5286366B2 (es)
KR (2) KR101187111B1 (es)
CN (1) CN101945866B (es)
AR (1) AR069628A1 (es)
AU (1) AU2008334659A1 (es)
BR (1) BRPI0821138A2 (es)
CA (1) CA2708793C (es)
CL (1) CL2008003688A1 (es)
CO (1) CO6290661A2 (es)
CR (1) CR11469A (es)
CU (1) CU20100119A7 (es)
EA (2) EA020205B1 (es)
EC (1) ECSP10010244A (es)
ES (1) ES2542878T3 (es)
GT (1) GT201000166A (es)
HN (1) HN2010001176A (es)
IL (1) IL206104A (es)
MA (1) MA31869B1 (es)
MY (1) MY156466A (es)
NZ (1) NZ585788A (es)
PE (1) PE20091108A1 (es)
TN (1) TN2010000254A1 (es)
TW (1) TWI430804B (es)
WO (1) WO2009074605A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060977A1 (es) * 2006-05-31 2008-07-23 Novartis Ag Aminotiazoles y sus usos
ES2542878T3 (es) * 2007-12-12 2015-08-12 Novartis Ag Un derivado de aminotiazol como agente antibacteriano
WO2016081825A1 (en) 2014-11-21 2016-05-26 KamTek, Inc. Methods and compositions for treating clostridium difficile associated disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202241A (en) 1988-09-09 1993-04-13 Gruppo Lepetit S.P.A. Antibiotic GE 2270
ATE117724T1 (de) 1989-07-04 1995-02-15 Lepetit Spa Antibiotikum ge 22270, faktoren a1,a2,a3 und h.
ES2071143T3 (es) 1990-03-08 1995-06-16 Lepetit Spa Factores b1, b2, c1, c2, d1, d2, e y t del antibiotico ge 2270.
IL100572A (en) * 1991-01-03 1997-01-10 Lepetit Spa Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
EP0529410B1 (en) 1991-08-30 1998-02-25 Biosearch Italia S.p.A. Antibiotic GE 2270 factor C2a
US5882900A (en) 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
DE69317058T2 (de) 1992-12-22 1998-06-10 Biosearch Italia Spa Die antibiotika ge 37468 a, b und c
AU3805295A (en) 1994-11-08 1996-05-31 Gruppo Lepetit S.P.A. Microbial transformation process for obtaining antibiotic ge 2270 factor d2
DK0808326T3 (da) 1995-02-07 2001-10-01 Biosearch Italia Spa Basiske oxazolinamidderivater af GE2270 og GE2270-lignende antibiotika
DE69600244T2 (de) 1995-02-07 1998-10-01 Biosearch Italia Spa Basische prolinamid derivate von ge2270 und ge2270-ahnlichten antibiotika
JP2000505438A (ja) 1996-02-14 2000-05-09 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ 抗生物質ＧＥ２２７０因子Ｃ▲下２ａ▼、Ｄ▲下２▼およびＥの誘導体
JPH1059997A (ja) 1996-08-22 1998-03-03 Microbial Chem Res Found アミチアマイシンアミド誘導体
EP1553967B1 (en) 2002-06-17 2011-05-18 NAICONS s.c.a.r.l. Use of amide derivative of ge 2270 factor a3 for the treatment of acne
CA2580882A1 (en) 2004-09-22 2006-08-17 Merck & Co., Inc. Antibiotic compound
WO2007007399A1 (ja) * 2005-07-13 2007-01-18 Taisho Pharmaceutical Co., Ltd. チアゾール系化合物
AR060977A1 (es) 2006-05-31 2008-07-23 Novartis Ag Aminotiazoles y sus usos
ATE500259T1 (de) 2006-12-20 2011-03-15 Novartis Ag Aminothiazolmakrocyclen, ihre verwendung als antibakterielle verbindungen und verfahren zu ihrer herstellung
MX2009013214A (es) 2007-06-04 2010-01-15 Novartis Ag Macrociclos y sus usos.
ES2542878T3 (es) * 2007-12-12 2015-08-12 Novartis Ag Un derivado de aminotiazol como agente antibacteriano

Also Published As

Publication number Publication date
KR101187111B1 (ko) 2012-09-28
CA2708793C (en) 2016-06-21
JP2013189468A (ja) 2013-09-26
EA201000890A1 (ru) 2011-02-28
CN101945866B (zh) 2013-06-19
ES2542878T3 (es) 2015-08-12
JP5286366B2 (ja) 2013-09-11
CR11469A (es) 2010-07-09
US9492496B2 (en) 2016-11-15
JP2011506394A (ja) 2011-03-03
US20140274878A1 (en) 2014-09-18
BRPI0821138A2 (pt) 2015-06-16
CN101945866A (zh) 2011-01-12
IL206104A (en) 2015-03-31
MA31869B1 (fr) 2010-11-01
US20130231275A1 (en) 2013-09-05
US20090156628A1 (en) 2009-06-18
CU20100119A7 (es) 2011-10-14
KR20120047335A (ko) 2012-05-11
AR069628A1 (es) 2010-02-03
ECSP10010244A (es) 2010-07-30
NZ585788A (en) 2011-07-29
CL2008003688A1 (es) 2009-06-19
TN2010000254A1 (en) 2011-11-11
KR20100090809A (ko) 2010-08-17
US8426356B2 (en) 2013-04-23
CO6290661A2 (es) 2011-06-20
HN2010001176A (es) 2012-12-10
TW200932256A (en) 2009-08-01
CU23908B1 (es) 2013-06-28
EP2229386A1 (en) 2010-09-22
IL206104A0 (en) 2010-11-30
US20170015704A1 (en) 2017-01-19
GT201000166A (es) 2012-04-30
AU2008334659A1 (en) 2009-06-18
EP2229386B1 (en) 2015-06-03
CA2708793A1 (en) 2009-06-18
EA020205B1 (ru) 2014-09-30
MY156466A (en) 2016-02-26
WO2009074605A1 (en) 2009-06-18
EA201400280A1 (ru) 2014-08-29
TWI430804B (zh) 2014-03-21

Similar Documents

Publication Publication Date Title
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
PE20140161A1 (es) Compuesto biciclico
PE20120632A1 (es) Inhibidores de bace
PE20141371A1 (es) Compuestos heterociclicos y usos de los mismos
PE20120691A1 (es) Derivados de n1-sulfonil-5-fluoropirimidinona
PE20110547A1 (es) Compuestos de isoindolina con actividad anticancerigena
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
UY30732A1 (es) Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables
CL2011002016A1 (es) Compuestos derivados de benzimidazol con actividad inhibidora de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; utiles en el tratamiento de una infeccion por el virus de la hepatitis c (vhc).
PE20141359A1 (es) Compuestos y metodos para mejorar las respuestas inmunitarias innatas
AR065439A1 (es) Derivados de tiazoles 1,3 no condensados,composiciones farmaceuticas que los contienen y usos como agentes antivirales, en particular anti hiv.
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
CL2014000458A1 (es) Compuestos derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina; composicion y combinacion farmaceutica; y uso en el tratamiento o en la prevencion del alzheimer, diabetes tipo 2, obesidad, entre otras enfermedades.
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20091237A1 (es) Derivados de pirrolidina como moduladores de serina proteasas
AR063684A1 (es) Derivados de 4, 4´-bifenildiilbis(1h-imidazol-5, 2-diil) como inhibidores del virus de la hepatitis c, composicion que los comprende y su uso para tratar una infeccion con vhc.
PE20190711A1 (es) N-(fenils ulfonil) benzamidas y compuestos relacionados como inhibidores de bcl-2
PE20191652A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
PE20130157A1 (es) Inhibidores de la polimerasa virica
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
PE20141199A1 (es) Depsipeptidos ciclicos como moduladores de calicreina 7

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed